Martina Schneider

Valneva (Austria) — Austria

Medicine · Health Sciences

36h-index5.7kcitations186works10.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(14), Cancer Immunotherapy and Biomarkers(10), Mosquito-borne diseases and control(9), Bladder and Urothelial Cancer Treatments(8), Cytomegalovirus and herpesvirus research(8)

Publications184 total

Live-attenuated chikungunya vaccine in children: a randomized phase 2 trial
Nature Medicine·2026
Streptokokkus pneumoniae – seltener Fall einer Late-onset-Sepsis beim Reifgeborenen
Zeitschrift für Geburtshilfe und Neonatologie·2025
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents
The Lancet Infectious Diseases·2024· 28 cited
Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study
The Lancet Infectious Diseases·2024· 29 cited
NeoTRACK-Studie: Neoadjuvante und adjuvante Immunchemotherapie (Tiragolumab/Atezolizumab/Platin) beim operablen fortgeschrittenen nicht-kleinzelligen Lungenkarzinom
Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie·2024
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial
The Lancet Infectious Diseases·2024· 12 cited
Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies
The Lancet Infectious Diseases·2024· 25 cited
Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine
British Journal of Urology·2024· 3 cited
The comorbidity profiles and medication issues of patients with multiple system atrophy: a systematic cross-sectional analysis
Journal of Neurology·2024· 6 citedOpen Access
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
European Journal of Cancer·2024· 6 citedOpen Access
Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC): A multicenter, single arm phase 2 trial (SAKK 06/19).
Journal of Clinical Oncology·2024· 1 cited
A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults
Journal of Travel Medicine·2023· 32 citedOpen Access
Timber Traceability: A Diagnostic Tool for Practitioners and Policymakers
2023· 4 citedOpen Access
Mapping Cocoa and Assessing Deforestation Risk for the Cocoa Sector in Côte d’Ivoire and Ghana
2023· 3 citedOpen Access
[Individual Needs of the Patient in Breast Reconstruction - Are There Limits to Plastic Surgery?]
PubMed·2023
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17
Journal of Clinical Oncology·2023· 39 citedOpen Access
First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2): Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
Journal of Clinical Oncology·2023· 2 cited
Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy – protocol of a multicentre, single arm phase 2 trial (SAKK 06/19)
BMJ Open·2023· 6 citedOpen Access
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
The Lancet·2023· 192 citedOpen Access
Corrigendum to ‘Substances from unregulated drug markets – A retrospective data analysis of customer-provided samples from a decade of drug checking service in Zurich (Switzerland)’ [Volume 114, April 2023, 103972]
International Journal of Drug Policy·2023Open Access
page 1 of 10Next →

Frequent Co-authors

Laurent Lagrost(6), Romana Hochreiter(6), Karin Kosulin(6), Katrin Dubischar(6), Susanne Eder-Lingelbach(6), Nina Wressnigg(6), Meinrad Gawaz(6), Oliver Zoihsl(5), Stefan Baumgartner(5), Kai‐Uwe Goss(5), Tobias Geisler(5), Sandra Hadl(4), Robert M. Mader(4), Vera Buerger(4), Valérie Deckert(4), Catherine Desrumaux(4), Karin Müller(4), Iris Müller(4), Alexis Klein(3), Robert P. McMahon(3)